ByHeart Infant Botulism Outbreak Declared Over After Affecting 48 Babies
Federal health authorities have announced the conclusion of a rare infant botulism outbreak connected to recalled ByHeart baby formula, with no new cases reported since mid-December. The U.S. Centers for Disease Control and Prevention confirmed on Thursday that 48 babies were hospitalised during the incident, a figure revised downward from earlier counts after three infants were diagnosed with unrelated illnesses.
Unprecedented Scale and Unresolved Contamination Source
Health officials emphasised that the outbreak's size and scope are unprecedented for illnesses caused by botulism bacteria in infant formula. The exact source, timing, and method of contamination in the organic, whole-milk powdered formula remain undetermined. The bacteria can cause severe illness, paralysis, and death in children under one year old.
Most cases emerged from August onwards, following alerts from California's Infant Botulism Treatment and Prevention program about a concerning rise in illnesses among babies consuming ByHeart products. New York-based ByHeart initiated a recall of two formula lots in early November, swiftly expanding it to all products. Federal officials later indicated contamination could not be ruled out in items produced since the company's March 2022 launch, prompting nationwide store removals of the formula marketed for its "next-to-breast milk benefits."
Ongoing Investigation and Treatment Challenges
Investigators from the U.S. Food and Drug Administration have yet to pinpoint the root cause. The agency reported identifying 17 different strains of the illness-causing bacteria in samples from patients, finished formula cans, and ingredients. While these findings contribute to evidence, they are not definitive. Previously, FDA officials suggested powdered whole milk used in ByHeart formula might be a contamination source.
Infant botulism occurs when babies ingest spores that germinate in the intestine, producing a toxin that attacks the nervous system. Historically fatal in up to 90% of cases, modern treatment has reduced death rates to below 1%. The sole treatment is BabyBIG, an IV medication derived from the blood plasma of immunised adults, exclusively supplied by California's program.
Market Impact and Parental Choices
ByHeart, which held approximately 1% of the U.S. infant formula market, previously sold around 200,000 cans monthly. Parents of affected babies reported choosing the formula, priced at about $42 per can, due to its promoted health advantages. No deaths have been reported in this outbreak, though all sickened children required hospitalisation.
